Neal D. Shore, MD, FACS Elected to LUGPA Board of Directors

Neal D. Shore, MD, FACS, is elected to LUGPA Board of Directors

Chicago, Ill. (November 15, 2017) – Neal D. Shore, MD, FACS, was re-elected to an additional one-year term as President of LUGPA’s 2017 Board of Directors at the 2017 Annual Meeting in Chicago, November 10-11.

Prior to his recent re-election, Dr. Shore served as LUGPA President in 2017, LUGPA President-Elect, from 2014-2016 and LUGPA Secretary from 2011-2013. He has served as a founding member of the LUGPA Board of Directors since 2009.

“I am honored to be re-elected LUGPA President,” said Dr. Shore. “After leading LUGPA for the past year, I am committed to continue LUGPA’s advocacy to advance the success of an independent integrated model of urologic care by developing and introducing innovative products, programs and services to support its member urology practices.”

Dr. Shore is the medical director of the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He has conducted more than 300 clinical trials focusing mainly on GU Oncology.

A graduate of Duke University, and Duke University Medical School, Dr. Shore completed a six-month clinical research fellowship in Pretoria, South Africa, and then completed his general surgery/urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a fellow of the American College of Surgeons.

In addition to LUGPA’s board, Dr. Shore serves on the executive boards of: Society of Urologic Oncology and Society of Urologic Oncology-Clinical Trials Consortium. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer. He serves on the boards of the Bladder Cancer Advocacy Network, the Bladder Cancer Advisory Think Tank ,and the editorial boards of Everyday Urology-Oncology, World Journal of Urology, Urology Times, Current Urology Reports, Chemotherapy Advisor, OncLive, PlosOne and Urology Practice. He has written more than 150 peer reviewed publications and book chapters.

LUGPA has currently grown to represent more than 25 percent of the nation’s urology practices, comprising more than 2,300 members, whom account for approximately 30 percent of urologic care in the United States. The Association is committed to providing the best resources and information for its member practices through advocacy, research, data collection and benchmarking efforts. LUGPA advocates for independent urology practices by promoting quality clinical outcomes, fostering new opportunities for clinical care advancements, and maintaining its advocacy in the legislative and regulatory arenas.